These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20947617)

  • 1. Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
    Zhang F; Tagen M; Throm S; Mallari J; Miller L; Guy RK; Dyer MA; Williams RT; Roussel MF; Nemeth K; Zhu F; Zhang J; Lu M; Panetta JC; Boulos N; Stewart CF
    Drug Metab Dispos; 2011 Jan; 39(1):15-21. PubMed ID: 20947617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.
    Brennan RC; Federico S; Bradley C; Zhang J; Flores-Otero J; Wilson M; Stewart C; Zhu F; Guy K; Dyer MA
    Cancer Res; 2011 Jun; 71(12):4205-13. PubMed ID: 21515735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).
    Bai F; Zhu F; Tagen M; Miller L; Owens TS; Mallari J; Derrick E; Zhang F; Stewart CF
    J Pharm Biomed Anal; 2010 Mar; 51(4):915-20. PubMed ID: 19931997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
    Michaelis M; Rothweiler F; Klassert D; von Deimling A; Weber K; Fehse B; Kammerer B; Doerr HW; Cinatl J
    Cancer Res; 2009 Jan; 69(2):416-21. PubMed ID: 19147553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nutlin sensitizes lung carcinoma cells to interferon-alpha treatment in MDM2-dependent but p53-independent manner.
    Shuvalov O; Kizenko A; Shakirova A; Fedorova O; Petukhov A; Aksenov N; Vasileva E; Daks A; Barlev N
    Biochem Biophys Res Commun; 2018 Jan; 495(1):1233-1239. PubMed ID: 29175211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.
    Tonsing-Carter E; Bailey BJ; Saadatzadeh MR; Ding J; Wang H; Sinn AL; Peterman KM; Spragins TK; Silver JM; Sprouse AA; Georgiadis TM; Gunter TZ; Long EC; Minto RE; Marchal CC; Batuello CN; Safa AR; Hanenberg H; Territo PR; Sandusky GE; Mayo LD; Eischen CM; Shannon HE; Pollok KE
    Mol Cancer Ther; 2015 Dec; 14(12):2850-63. PubMed ID: 26494859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted nutlin-3a loaded nanoparticles inhibiting p53-MDM2 interaction: novel strategy for breast cancer therapy.
    Das M; Dilnawaz F; Sahoo SK
    Nanomedicine (Lond); 2011 Apr; 6(3):489-507. PubMed ID: 21542687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hydrophobically-tagged MDM2-p53 interaction inhibitor Nutlin-3a-HT is more potent against tumor cells than Nutlin-3a.
    Nietzold F; Rubner S; Berg T
    Chem Commun (Camb); 2019 Nov; 55(95):14351-14354. PubMed ID: 31720601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells.
    Elison JR; Cobrinik D; Claros N; Abramson DH; Lee TC
    Arch Ophthalmol; 2006 Sep; 124(9):1269-75. PubMed ID: 16966622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
    Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nutlin-3a selects for cells harbouring TP53 mutations.
    Kucab JE; Hollstein M; Arlt VM; Phillips DH
    Int J Cancer; 2017 Feb; 140(4):877-887. PubMed ID: 27813088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients.
    Trino S; Iacobucci I; Erriquez D; Laurenzana I; De Luca L; Ferrari A; Ghelli Luserna Di Rorà A; Papayannidis C; Derenzini E; Simonetti G; Lonetti A; Venturi C; Cattina F; Ottaviani E; Abbenante MC; Russo D; Perini G; Musto P; Martinelli G
    Oncotarget; 2016 Mar; 7(11):12951-61. PubMed ID: 26887044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells.
    Shen H; Maki CG
    J Cell Biochem; 2010 Dec; 111(5):1280-90. PubMed ID: 20803550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation.
    Borthakur G; Duvvuri S; Ruvolo V; Tripathi DN; Piya S; Burks J; Jacamo R; Kojima K; Ruvolo P; Fueyo-Margareto J; Konopleva M; Andreeff M
    PLoS One; 2015; 10(10):e0139254. PubMed ID: 26440941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
    Peirce SK; Findley HW
    Int J Oncol; 2009 May; 34(5):1395-402. PubMed ID: 19360352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals.
    Candido S; Abrams SL; Steelman LS; Lertpiriyapong K; Martelli AM; Cocco L; Ratti S; Follo MY; Murata RM; Rosalen PL; Bueno-Silva B; de Alencar SM; Lombardi P; Mao W; Montalto G; Cervello M; Rakus D; Gizak A; Lin HL; Libra M; Akula SM; McCubrey JA
    Adv Biol Regul; 2019 May; 72():22-40. PubMed ID: 30898612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
    Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.